In last trading session, Prothena Corporation plc (NASDAQ:PRTA) saw 0.79 million shares changing hands with its beta currently measuring -0.04. Company’s recent per share price level of $6.26 trading at -$0.21 or -3.25% at ring of the bell on the day assigns it a market valuation of $336.96M. That closing price of PRTA’s stock is at a discount of -306.07% from its 52-week high price of $25.42 and is indicating a premium of 30.99% from its 52-week low price of $4.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.88 million shares which gives us an average trading volume of 1.81 million if we extend that period to 3-months.
For Prothena Corporation plc (PRTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.12. Splitting up the data highlights that, out of 15 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.79 in the current quarter.
Prothena Corporation plc (NASDAQ:PRTA) trade information
Prothena Corporation plc’s shares saw a change of -74.06% in year-to-date performance and have moved -2.19% in past 5-day. Prothena Corporation plc (NASDAQ:PRTA) showed a performance of 9.82% in past 30-days. Number of shares sold short was 4.66 million shares which calculate 2.24 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 56 to the stock, which implies a rise of 88.82% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 98. It follows that stock’s current price would drop -283.39% in reaching the projected high whereas dropping to the targeted low would mean a loss of -283.39% for stock’s current value.
Prothena Corporation plc (PRTA) estimates and forecasts
This year revenue growth is estimated to fall -78.27% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.18M for the same. And 9 analysts are in estimates of company making revenue of 6.18M in the next quarter. Company posted 132.01M and 970k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -3.15% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -71.81% while estimates for its earnings growth in next 5 years are of -1.63%.
Prothena Corporation plc (NASDAQ:PRTA)’s Major holders
Insiders are in possession of 18.98% of company’s total shares while institution are holding 73.95 percent of that, with stock having share float percentage of 91.28%. Investors also watch the number of corporate investors in a company very closely, which is 73.95% institutions for Prothena Corporation plc that are currently holding shares of the company. ECOR1 CAPITAL, LLC is the top institutional holder at PRTA for having 11.58 million shares of worth $239.1 million. And as of 2024-06-30, it was holding 21.5453 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 8.07 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.0012 of outstanding shares, having a total worth of $166.48 million.
On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Apr 30, 2025, the former fund manager was holding 4.18 shares of worth $26.19 million or 7.77% of the total outstanding shares. The later fund manager was in possession of 2.32 shares on May 31, 2025, making its stake of worth around $14.55 million in the company or a holder of 4.32% of company’s stock.
